CagriSema, which underperformed expectations in its first Phase 3 test, will be studied at different doses and for longer ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback